Key result
Chronic kidney disease was associated with attenuated sympathetic baroreflex sensitivity (-1.34 vs -2.91 bursts/100 heartbeats/mmHg; P=0.001) and reduced sympathetic-BP transduction.
Why the study?
Whether sympathetic baroreflex sensitivity is impaired or intact in CKD remains under-studied and controversial, and the downstream effect of sympathetic activation on blood pressure transduction has not been examined.
Is sympathetic baroreflex sensitivity and sympathetic-blood pressure transduction impaired in patients with chronic kidney disease compared to age-matched controls?
Case-Control (n=31)
Is sympathetic baroreflex sensitivity and sympathetic-blood pressure transduction impaired in patients with chronic kidney disease compared to age-matched controls?
Absolute Event Rate: -1.34% vs -2.91%
p-value: p=0.001
Patients with CKD stages III-IV exhibit impaired sympathetic baroreflex sensitivity and attenuated sympathetic-blood pressure transduction, which may contribute to sympathetic overactivation while counteracting its vascular effects.
Impaired sBRS in CKD may heighten SNS-driven risk; leaves open whether baroreflex-targeted interventions improve outcomes.
Chronic kidney disease (CKD) is characterized by over-activation of the sympathetic nervous system (SNS) that increases cardiovascular risk. Whether sympathetic baroreflex sensitivity (sBRS) is impaired or intact in CKD remains under-studied and controversial. Furthermore, the downstream effect of SNS activation on blood pressure transduction has not been previously examined in CKD. We tested the hypothesis that sBRS is attenuated, while sympathetic transduction is augmented in CKD. In 18 sedentary patients with CKD stages III-IV (eGFR: 40±14 mL/min) and 13 age-matched controls (eGFR: 95±10 mL/min), beat-to-beat blood pressure (BP; finger photoplethysmography), heart rate (electrocardiography) and muscle sympathetic nerve activity (MSNA; microneurography) were recorded at rest for 10-min. Weighted linear regression analysis between MSNA burst incidence and diastolic BP was used to determine the spontaneous sBRS. Sympathetic-BP transduction was quantified using signal averaging, whereby the BP response to each MSNA burst was tracked over 15 cardiac cycles and averaged to derive the peak change in BP. Compared with controls, CKD patients had an attenuated sBRS [CKD: -1.34 ± 0.59 versus CON: -2.91 ± 1.09 bursts (100 heartbeats)-1 mmHg-1; P = 0.001]. |sBRS| was significantly associated with eGFR (r = 0.69, P < 0.001). CKD patients had attenuated sympathetic-BP transduction compared to controls (0.75 ± 0.7 vs. 1.60 ± 0.8 mmHg; P = 0.010). Resting MSNA was negatively associated with sympathetic transduction (r = -0.57, P = 0.002). CKD patients exhibit impaired sBRS that may contribute to SNS overactivation and cardiovascular risk in this patient population. In addition, CKD patients had an attenuated sympathetic transduction that may counteract the vascular effects of SNS overactivation.
No takes yet. Share an insight, caveat, or question.
Sabino‐Carvalho et al. (2024) conducted a case-control in Chronic kidney disease (n=31). Chronic kidney disease vs. Age-matched controls was evaluated on Sympathetic baroreflex sensitivity (sBRS) (p=0.001). Chronic kidney disease was associated with attenuated sympathetic baroreflex sensitivity (-1.34 vs -2.91 bursts/100 heartbeats/mmHg; P=0.001) and reduced sympathetic-BP transduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: